Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
The approved NHS pathways are: Wegovy (semaglutide) licensed for weight management via NICE TA875 (BMI 35+ with one condition, via tier 3 services) and NICE cardiovascular guidance April 2026 (BMI 27+ with established CVD, via GP) Mounjaro (tirzepatide) licensed for weight management via NICE TA1026 (BMI 35+ with four conditions from June 2026, via tier 3 or QOF GP pathway) Ozempic (semaglutide) NOT approved for NHS weight management
As with all prescriptions, GLP-1s arent right for everyonea licensed medical provider will review your health history to determine eligibility
This separation means they do not compete for the same liver enzymes or kidney filtration routes
Why Retatrutide Users Are at Risk Two factors combine to create dehydration risk
The drugs have proven so popular that the market value of the Danish company behind them recently exceeded the entire economy of Denmark
US$ 27.42
US$ 25.59
US$ 21.14
